ReviewCancer treatment reviews2018

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.

Robert L Ferris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.